CB-839/cabozantinib combination in advanced/metastatic kidney cancer fails to improve progression-free survival
The US Food and Drug Administration (FDA) has granted the [...]
FDA grants Fast Track designation to glutaminase inhibitor combination for metastatic kidney cancer
The glutaminase inhibitor, CB-839 has been granted Fast Track designation [...]
FDA grants fast track designation to glutaminase inhibitor CB-839 in combination with cabozantinib for metastatic kidney cancer
Calithera Biosciences announced earlier this week that the US Food [...]
New drug shows promise in combination with cabozantinib for the treatment of advanced kidney cancer
Results from a phase 1 clinical trial looking at CB-839, [...]
A new drug to treat solid tumours
The following blog from Mesothelioma.net gives a good summary of [...]
Initiation of phase 2 clinical trial of glutaminase inhibitor plus everolimus for renal cell carcinoma
Calithera Biosciences, an American pharmaceutical company focused on developing drugs [...]
FDA grants fast track designation to new glutaminase inhibitor CB-839 for metastatic kidney cancer
Calithera Biosciences announced yesterday that the FDA has granted fast [...]
New drug shows promise in kidney cancer in combination with everolimus
A new drug that targets a key enzyme that cancer [...]
